علاج النقائل الدماغية في سرطان الثدي السلبي لـ HER2 بعد العلاج الموضعي السابق

References

For HER2-negative breast cancer patients with progressive BM after local treatment, standard chemotherapy, such as capecitabine, eribulin or carboplatin and bevacizumab, may be considered.

Abemaciclib showed an intracranial clinical benefit rate defined as complete response plus partial response plus stable disease persisting for 6 months of 25% and a median progression-free survival (PFS) of 4.4 months in heavily pre-treated patients with BM from estrogen receptor-positive/HER2-negative breast cancer.

DOI: 10.1016/j.annonc.2021.07.016